- Home
- IRMD vs TRVI Comparison
IRMD vs TRVI Comparison
Compare IRMD & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- TRVI
- Stock Information
- Founded
- IRMD 1992
- TRVI 2011
- Country
- IRMD United States
- TRVI United States
- Employees
- IRMD 160
- TRVI N/A
- Industry
- IRMD Medical/Dental Instruments
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- IRMD Health Care
- TRVI Health Care
- Exchange
- IRMD Nasdaq
- TRVI Nasdaq
- Market Cap
- IRMD 668.2M
- TRVI 629.8M
- IPO Year
- IRMD 2014
- TRVI 2019
- Fundamental
- Price
- IRMD $57.99
- TRVI $5.76
- Analyst Decision
- IRMD Strong Buy
- TRVI Strong Buy
- Analyst Count
- IRMD 1
- TRVI 8
- Target Price
- IRMD $72.00
- TRVI $19.31
- AVG Volume (30 Days)
- IRMD 34.7K
- TRVI 1.0M
- Earning Date
- IRMD 05-05-2025
- TRVI 05-08-2025
- Dividend Yield
- IRMD 1.18%
- TRVI N/A
- EPS Growth
- IRMD 10.72
- TRVI N/A
- EPS
- IRMD 1.55
- TRVI N/A
- Revenue
- IRMD $75,154,639.00
- TRVI N/A
- Revenue This Year
- IRMD $10.62
- TRVI N/A
- Revenue Next Year
- IRMD $9.69
- TRVI N/A
- P/E Ratio
- IRMD $37.35
- TRVI N/A
- Revenue Growth
- IRMD 11.04
- TRVI N/A
- 52 Week Low
- IRMD $41.69
- TRVI $2.30
- 52 Week High
- IRMD $63.29
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- IRMD 64.00
- TRVI 56.14
- Support Level
- IRMD $50.88
- TRVI $6.08
- Resistance Level
- IRMD $59.05
- TRVI $6.47
- Average True Range (ATR)
- IRMD 1.90
- TRVI 0.39
- MACD
- IRMD 0.57
- TRVI -0.00
- Stochastic Oscillator
- IRMD 83.54
- TRVI 45.06
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.